2 recruiting, 2 unknown, 1 active not recruiting, 1 completed. 7 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 7 | Recruiting 2, Unknown 2, Active not recruiting 1, Completed 1, Not yet recruiting 1 |
| Phase 2 | 1 | Unknown 1 |
Follow Adjuvant Therapy: new trials by email Literature Review of Adjuvant Therapy trials Research Report on Adjuvant Therapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Chemo-free in Older (≥65) Node-Positive ER+/HER2- Breast Cancer Chemotherapy, CDK4/6 Inhibitor, Endocrine therapy - Breast Cancer, Adjuvant Therapy | Phase 3 | Not yet recruiting | Fudan University | 1244 | 2025-06-15 | 2025-06-05 |
| CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS) Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane), Standard endocrine therapy combined with CDK4/6 Inhibitor - Breast Cancer, Adjuvant Therapy | Phase 3 | Recruiting | Fudan University | 1903 | 2025-06-15 | 2026-01-21 |
| Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations Befotertinib + Icotinib placebo, Icotinib + Befotertinib placebo - Non-Small Cell Lung Cancer, EGFR Sensitive Mutation | Phase 3 | Recruiting | Betta Pharmaceuticals Co., Ltd. | 570 | 2023-03-28 | 2023-09-22 |
| Efficacy and Safety of Adjuvant Docetaxel and Trastuzumab in Stage I HER2-positive Breast Cancer Paclitaxel, Trastuzumab, Docetaxel - HER2-positive Breast Cancer, Adjuvant Therapy | Phase 2 / Phase 3 | Unknown | Second Affiliated Hospital, Zhejiang University, School of Medicine | 190 | 2022-01-31 | 2022-01-12 |
| Sintilimab Plus Bevacizumab as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Curative Resection Sintilimab, Bevacizumab - HCC, Adjuvant Therapy | Phase 3 | Unknown | Sun Yat-sen University | 246 | 2020-12-01 | 2020-12-23 |
| A Trial of Aspirin on Recurrence and Survival in Colon Cancer Patients Acetylsalicylic acid, Placebo Acetylsalicylic acid - Colon Cancer, Adjuvant Therapy | Phase 3 | Active not recruiting | Leiden University | 770 | 2015-01-01 | 2024-03-18 |
| Nordic Adjuvant IFN Melanoma Trial Interferon-alpha2b - 1 year, Interferon-alpha2b - 2 years - Melanoma, Adjuvant Therapy | Phase 3 | Completed | Karolinska Institutet | 855 | 1996-11-01 | 2010-12-14 |
Breast Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (1) · Colonic Neoplasms (1) · Melanoma (1)
Neoplasms (5) · Neoplasms by Site (5) · Skin Diseases (3) · Skin and Connective Tissue Diseases (3) · Breast Diseases (2) · Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1) · Colonic Diseases (1) · Colorectal Neoplasms (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Gastrointestinal Diseases (1) · Gastrointestinal Neoplasms (1) · Intestinal Diseases (1) · Intestinal Neoplasms (1)
Anastrozole (1) · Aspirin (1) · Bevacizumab (1) · Docetaxel (1) · Drug Therapy (1) · Interferon-alpha2b (1) · Introns (1) · Letrozole (1) · Paclitaxel (1) · Protons (1) · Tamoxifen (1) · Trastuzumab (1) · exemestane (1) · icotinib (1) · sintilimab (1)
Fudan University (2) · Betta Pharmaceuticals Co., Ltd. (1) · Karolinska Institutet (1) · Leiden University (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1) · Sun Yat-sen University (1)
China (4) · Netherlands (1) · Sweden (1)
G.J. Liefers, MD PhD (1) · Hans von der Maase, MD PhD (1) · Johan Hansson, MD,PhD (1) · Lars Bastholt, MD,PhD (1) · Micaela Hernberg, MD, PhD (1) · R. Fodde, Professor (1) · Shun Lu, M.D. (1) · Steinar Aamdal, MD. PhD (1) · Tao Pan (1) · Ulrika Stierner, MD PhD (1) · Zhiming Shao (1)